How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Pancreatic Cancer
Zenocutuzumab Gets Orphan Drug Designation for Pancreatic Cancer
Zenocutuzumab is a first-in-class bispecific antibody that binds to HER2 and HER3 receptors, thereby blocking the interaction of HER3 with its ligand neuregulin 1 (NRG1) or NRG1-fusion proteins.
Why Cancer Centers May Need to Rethink the Hard Sell to Patients
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
NALIRIFOX Shows Promising Anticancer Activity in Metastatic Pancreatic Ductal Adenocarcinoma
The NALIRIFOX chemotherapy regimen includes liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Neoadjuvant Treatment of Borderline-Resectable Pancreatic Cancer Led to Improved Overall Survival
Neoadjuvant treatment with GEMCAP, FOLFIRINOX, or capecitabine plus radiotherapy prolonged OS compared with immediate surgery in patients with pancreatic cancer.
New-Onset Type 2 Diabetes as a Potential Biomarker in Pancreatic Cancer
The study results suggest that patients with weight loss after age 50 years in the context of new-onset type 2 diabetes may be good candidates for pancreatic cancer screening.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Clinical, Genetic, Biomarker Model IDs Risk for Pancreatic Cancer
Area under the ROC curve estimated by cross-validation was 0.62 for multifactor model.
-
Loading...
-
Loading...
Next post in Pancreatic Cancer
